TY - JOUR
T1 - The effect of long-term treatment with coenzyme Q10 on nucleic acid modifications by oxidation in children with Down syndrome
AU - Larsen, Emil List
AU - Padella, Lucia
AU - Bergholdt, Helle Kirstine Mørup
AU - Henriksen, Trine
AU - Santoro, Lucia
AU - Gabrielli, Orazio
AU - Poulsen, Henrik Enghusen
AU - Littarru, Gian Paolo
AU - Orlando, Patrick
AU - Tiano, Luca
N1 - Copyright © 2018 Elsevier Inc. All rights reserved.
PY - 2018/7
Y1 - 2018/7
N2 - Elevated levels of oxidative nucleic acid modifications have been proposed to be associated with some of the clinical characteristics of Down syndrome. Oral intake of coenzyme Q10 improves oxidative status and shows a tendency toward protective effect on DNA oxidation in certain age groups of children with Down syndrome. Here, we demonstrate that long-term (i.e., 4 years) treatment with coenzyme Q10 (ubiquinone) at the dosage of 4 mg/kg/d does not affect whole body DNA and RNA oxidation.
AB - Elevated levels of oxidative nucleic acid modifications have been proposed to be associated with some of the clinical characteristics of Down syndrome. Oral intake of coenzyme Q10 improves oxidative status and shows a tendency toward protective effect on DNA oxidation in certain age groups of children with Down syndrome. Here, we demonstrate that long-term (i.e., 4 years) treatment with coenzyme Q10 (ubiquinone) at the dosage of 4 mg/kg/d does not affect whole body DNA and RNA oxidation.
KW - Administration, Oral
KW - Biomarkers/urine
KW - Child
KW - DNA/metabolism
KW - Deoxyadenosines/urine
KW - Down Syndrome/drug therapy
KW - Guanine/analogs & derivatives
KW - Humans
KW - Oxidation-Reduction/drug effects
KW - Oxidative Stress/drug effects
KW - RNA/metabolism
KW - Time Factors
KW - Ubiquinone/administration & dosage
U2 - 10.1016/j.neurobiolaging.2018.03.001
DO - 10.1016/j.neurobiolaging.2018.03.001
M3 - Journal article
C2 - 29665577
SN - 0197-4580
VL - 67
SP - 159
EP - 161
JO - Neurobiology of Aging
JF - Neurobiology of Aging
ER -